History of the development of in vitro diagnostic reagents
In vitro diagnostic reagents [1 The current development status of the industry is very similar to the development of the home appliance industry in the early 1990s: on the one hand, the market is large; on the other hand, the monopoly advantage of imported reagents and diagnostic equipment is being broken and restricted by national products. . "This is a summary of the development status of in vitro diagnostic reagents in my country by Wu Lebin, the president of Zhongsheng Beikong Biotechnology Co., Ltd.
According to reports, the overall development of my country's in vitro diagnostic reagent industry shows the characteristics of a large developing country, that is, the market is large and the market potential is greater. At present, there are more than 18,000 hospitals and more than 300 blood stations in our country. At the same time, thousands of physical examination centers and hundreds of independent laboratories have sprung up like mushrooms after a rain. Some independent medical laboratory laboratories are also in the ascendant. The development of in vitro diagnostic reagents provides a broad market space.
China’s population accounts for 22% of the world’s total population, but the share of in vitro diagnostic reagents only accounts for 2% of the world’s total. Moreover, in recent years, the rise and fusion of various new technologies and methods has promoted the development and application of in vitro diagnostic reagents. And update. At the same time, with the increase of people's income and the improvement of living standards, people have higher demands for health and medical quality. Under various favorable conditions, the development of the in vitro diagnostic reagent industry has ushered in a golden opportunity in the history of medical development.
It is precisely because of this broad market prospect that large foreign medical imaging companies have begun to merge companies in the in vitro diagnostic industry. First, in 2006, after Siemens successively acquired the leading immunodiagnostic reagent supplier in the United States and the diagnostics department of Bayer of Germany, then GE acquired part of the in vitro diagnostic and rapid diagnostic reagent business of Abbott Pharmaceuticals for 8.13 billion, and several companies’ Merger operations are gradually "surfacing"
